- Home
- BSBR vs ZTS Comparison
BSBR vs ZTS Comparison
Compare BSBR & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BSBR | ZTS |
|---|---|---|
| Founded | 1985 | 1952 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.3B | 54.8B |
| IPO Year | 2009 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BSBR | ZTS |
|---|---|---|
| Price | $7.08 | $124.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $166.60 |
| AVG Volume (30 Days) | 840.9K | ★ 4.4M |
| Earning Date | 02-04-2026 | 02-12-2026 |
| Dividend Yield | ★ 3.91% | 1.71% |
| EPS Growth | N/A | ★ 11.64 |
| EPS | 0.60 | ★ 5.94 |
| Revenue | $8,325,806,268.00 | ★ $9,397,000,000.00 |
| Revenue This Year | $95.54 | $3.04 |
| Revenue Next Year | $6.59 | $4.96 |
| P/E Ratio | ★ $11.25 | $20.87 |
| Revenue Growth | N/A | ★ 2.68 |
| 52 Week Low | $4.23 | $115.25 |
| 52 Week High | $6.82 | $177.40 |
Technical Indicators
Market Signals| Indicator | BSBR | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 73.23 | 49.45 |
| Support Level | $6.11 | $122.97 |
| Resistance Level | $6.82 | $127.12 |
| Average True Range (ATR) | 0.13 | 2.87 |
| MACD | 0.08 | -0.21 |
| Stochastic Oscillator | 98.48 | 36.48 |
Price Performance
Historical ComparisonAbout BSBR Banco Santander Brasil SA each representing one unit
Banco Santander (Brasil) SA is part of Santander Group, a Spanish bank. It operates across two segments; the Commercial Banking segment, catering to both individual and corporate client and the Global Wholesale Banking segment, which encompasses Investment Banking and Markets operations, including the Treasury and Equity Business Departments. The bank generates majority of its revenue from the Commercial Banking segment and has operations in Brazil and internationally.
About ZTS Zoetis Inc.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its USA business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.